Cellulitis
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Ir-riġel huwa post komuni għal Cellulitis.
Każ tipiku
Fażi ta 'fejqan.
References
Cellulitis hija infezzjoni batterika komuni tal-ġilda. Taffettwa aktar minn 14-il miljun ruħ fis-sena fl-Istati Uniti. Dan iwassal għal madwar $ 3. 7 biljun fi spejjeż ta 'kura ambulatorja u 650,000 dħul fl-isptar kull sena. Tipikament, cellulitis tidher bħala żona sħuna u ħamra fuq il-ġilda b'nefħa u sensittività. Hija kkawżata minn infezzjoni batterjali f'daqqa li tikkawża infjammazzjoni fis-saffi tal-ġilda fil-fond u fit-tessut fil-qrib. M'hemm l-ebda axxess jew timbotta b'din l-infezzjoni. Streptococcus beta-emolitiċi, speċjalment streptococcus tal-grupp A (Streptococcus pyogenes) , huma l-ħatja tas-soltu, segwiti minn methicillin-sensitive Staphylococcus aureus.
Cellulitis is a common bacterial skin infection, with over 14 million cases occurring in the United States annually. It accounts for approximately 3.7 billion dollars in ambulatory care costs and 650000 hospitalizations annually. Cellulitis typically presents as a poorly demarcated, warm, erythematous area with associated edema and tenderness to palpation. It is an acute bacterial infection causing inflammation of the deep dermis and surrounding subcutaneous tissue. The infection is without an abscess or purulent discharge. Beta-hemolytic streptococci typically cause cellulitis, generally group A streptococcus (i.e., Streptococcus pyogenes), followed by methicillin-sensitive Staphylococcus aureus. Patients who are immunocompromised, colonized with methicillin-resistant Staphylococcus aureus, bitten by animals, or have comorbidities such as diabetes mellitus may become infected with other bacteria.
Cellulitis is a common bacterial skin infection, with over 14 million cases occurring in the United States annually. It accounts for approximately 3.7 billion dollars in ambulatory care costs and 650000 hospitalizations annually. Cellulitis typically presents as a poorly demarcated, warm, erythematous area with associated edema and tenderness to palpation. It is an acute bacterial infection causing inflammation of the deep dermis and surrounding subcutaneous tissue. The infection is without an abscess or purulent discharge. Beta-hemolytic streptococci typically cause cellulitis, generally group A streptococcus (i.e., Streptococcus pyogenes), followed by methicillin-sensitive Staphylococcus aureus. Patients who are immunocompromised, colonized with methicillin-resistant Staphylococcus aureus, bitten by animals, or have comorbidities such as diabetes mellitus may become infected with other bacteria.
Cellulitis hija infezzjoni batterjali tal-ġilda u tat-tessuti rotob. Dan jiġri meta jkun hemm problemi bil-barriera protettiva tal-ġilda, is-sistema immuni, jew iċ-ċirkolazzjoni tad-demm. Id-dijabete, l-obeżità, u x-xjuħija jżidu ċ-ċansijiet ta cellulitis billi jaffettwaw dawn l-oqsma. Inħarsu wkoll lejn is-sejbiet reċenti dwar id-dijanjosi cellulitis , li jenfasizzaw l-importanza ta 'dijanjosi preċiża peress li kundizzjonijiet bħal insuffiċjenza tal-vini, ekżema, trombożi tal-vini fil-fond, u gotta ħafna drabi huma konfużi ma' ċellulite. L-antibijotiċi użati biex jittrattaw cellulitis jintgħażlu bir-reqqa biex jimmiraw batterji komuni mingħajr ma tinkoraġġixxi r-reżistenza għall-antibijotiċi. Nitkellmu wkoll dwar antibijotiċi ġodda approvati għal cellulitis. Cellulitis ta’ spiss terġa’ lura minħabba fatturi ta’ riskju li għaddejjin u ħsara lis-sistema limfatika. .
Cellulitis is a bacterial infection of the skin and soft tissues. It happens when there are issues with the skin's protective barrier, the immune system, or blood circulation. Diabetes, obesity, and old age increase the chances of cellulitis by affecting these areas. We also look at recent findings on diagnosing cellulitis, highlighting the importance of accurate diagnosis since conditions like venous insufficiency, eczema, deep vein thrombosis, and gout are often confused with cellulitis. Antibiotics used to treat cellulitis are chosen carefully to target common bacteria without encouraging antibiotic resistance. We also talk about new antibiotics approved for cellulitis. Cellulitis often comes back because of ongoing risk factors and damage to the lymphatic system..
Cellulitis is a bacterial infection of the skin and soft tissues. It happens when there are issues with the skin's protective barrier, the immune system, or blood circulation. Diabetes, obesity, and old age increase the chances of cellulitis by affecting these areas. We also look at recent findings on diagnosing cellulitis, highlighting the importance of accurate diagnosis since conditions like venous insufficiency, eczema, deep vein thrombosis, and gout are often confused with cellulitis. Antibiotics used to treat cellulitis are chosen carefully to target common bacteria without encouraging antibiotic resistance. We also talk about new antibiotics approved for cellulitis. Cellulitis often comes back because of ongoing risk factors and damage to the lymphatic system..
Ħafna nies imorru sptarijiet jew kmamar ta 'emerġenza għal infezzjonijiet batteriċi tal-ġilda f'daqqa. Staphylococcus aureus huwa r-raħs ewlieni li jikkawża dawn l-infezzjonijiet, u qed isir aktar diffiċli biex tikkura minħabba li xi razez huma reżistenti għall-antibijotiċi komuni.
Acute bacterial skin and skin-structure infections are a common reason for seeking care at acute healthcare facilities, including emergency departments. Staphylococcus aureus is the most common organism associated with these infections, and the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) has represented a considerable challenge in their treatment.
Acute bacterial skin and skin-structure infections are a common reason for seeking care at acute healthcare facilities, including emergency departments. Staphylococcus aureus is the most common organism associated with these infections, and the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) has represented a considerable challenge in their treatment.
Staphylococcus aureus jistgħu jinqasmu f'żewġ tipi bbażati fuq ir-rispons tagħhom għall-antibijotiċi: methicillin-sensitive Staphylococcus aureus (MSSA) , methicillin-resistant Staphylococcus aureus (MRSA) . Matul l-aħħar ftit deċennji, minħabba l-evoluzzjoni tal-batterja u l-użu żejjed tal-antibijotiċi, ir-reżistenza ta ' S. Aureus għad-drogi kienet qed tiżdied, li wasslet għal żieda globali fir-rati ta' infezzjoni MRSA.
According to the sensitivity to antibiotic drugs, S. aureus can be divided into methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). In recent decades, due to the evolution of bacteria and the abuse of antibiotics, the drug resistance of S. aureus has gradually increased, the infection rate of MRSA has increased worldwide.
According to the sensitivity to antibiotic drugs, S. aureus can be divided into methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). In recent decades, due to the evolution of bacteria and the abuse of antibiotics, the drug resistance of S. aureus has gradually increased, the infection rate of MRSA has increased worldwide.
To review the salient features of the management of severe skin and soft tissue infections (SSTIs), including toxic shock syndrome, myonecrosis/gas gangrene, and necrotizing fasciitis.
Ir-riġlejn u l-wiċċ huma l-aktar siti komuni involuti. Fatturi ta 'riskju jinkludu l-obeżità, nefħa tar-riġlejn, u x-xjuħija. Il-batterji l-aktar komunement involuti huma streptococcus u Staphylococcus aureus.
It-trattament huwa tipikament b'antibijotiċi meħuda mill-ħalq, bħal cephalexin, amoxicillin jew cloxacillin. Madwar 95% tan-nies huma aħjar wara 7 sa 10 ijiem ta 'trattament. Dawk bid-dijabete, madankollu, ħafna drabi jkollhom riżultati agħar.
Iċ-ċellulite hija disturb komuni, u fir-Renju Unit, iċ-ċellulite kienet ir-raġuni għal 1.6% tad-dħul fi sptar. Iċ-ċellulite fl-2015 irriżulta f'madwar 16,900 mewt madwar id-dinja.
○ Trattament - Drogi OTC
Ċellulite avvanzata teħtieġ trattament b'antibijotiċi preskritti biss minn tabib. Jekk il-leżjoni tavvanza malajr u tkun akkumpanjata minn deni u bard, huwa rakkomandabbli li tara tabib kemm jista 'jkun malajr.
L-applikazzjoni ta 'ingwent antibijotiku mingħajr riċetta għal leżjonijiet bikrija tista' tgħin. Jekk l-ingwent jiġi applikat irqiq wisq, jista 'ma jaħdem xejn.
#Polysporin
#Bacitracin
#Betadine
Uża mediċini li jtaffu l-uġigħ OTC bħal acetaminophen biex ittaffi l-uġigħ.
#Ibuprofen
#Naproxen
#Acetaminophen
Żomm is-saqajn nodfa u kkura s-sieq tal-atleta minħabba li s-sieq tal-atleta żżid ir-riskju ta 'ċellulite.
○ Trattament
#First-generation cephalosporins (e.g. Cefradine)
#Bacterial culture
#Third-generation cephalosporins (e.g. Cefditoren Pivoxil)